Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AX Other antipsychotics
N05AX13 Paliperidone
D05339 Paliperidone (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antipsychotics
2nd Generation/Atypical
Paliperidone
D05339 Paliperidone (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
117 Psychotropics
1179 Others
D05339 Paliperidone (JAN/USP/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG00907 Paliperidone
D05339 Paliperidone
DG03005 Serotonin-dopamine antagonist (SDA)
DG00907 Paliperidone
D05339 Paliperidone
DG03200 Antipsychotic agent
DG03064 Atypical antipsychotic
DG00907 Paliperidone
D05339 Paliperidone
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D05339 Paliperidone (JAN/USP/INN) <JP/US>
Serotonin
HTR2A
D05339 Paliperidone (JAN/USP/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D05339
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D05339
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D05339
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D05339
Prodrugs [br08324.html]
D05339
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG00907 Paliperidone
DG03005 Serotonin-dopamine antagonist (SDA)
DG00907 Paliperidone
DG03200 Antipsychotic agent
DG03064 Atypical antipsychotic
DG00907 Paliperidone
Prodrugs [br08324.html]
DG00907